Carta Acesso aberto Revisado por pares

Remission in SLE: closing in on the target

2015; BMJ; Volume: 74; Issue: 12 Linguagem: Inglês

10.1136/annrheumdis-2015-208231

ISSN

1468-2060

Autores

Ronald van Vollenhoven, Alexandre E. Voskuyl, Eric F. Morand, Cynthia Aranow,

Tópico(s)

Lymphoma Diagnosis and Treatment

Resumo

I'm in complete remission. I'm alive and well.Gene Wilder Over the past decades, the concept of ‘remission’ has emerged as a moniker for the disease state one would ideally like to achieve when a ‘cure’—the ultimate goal of medical intervention—cannot realistically be hoped for. Originally used in oncology to describe the absence of detectable tumour, remission has become an important concept among medical specialties treating autoimmune inflammatory diseases. In some of these disease areas, three distinct processes have taken place: Needless to say, these three developments have strongly influenced each other. Thus, the existence of specific and quantitative definitions of remission made it possible to articulate it as a therapeutic target, and has made the term remission a topic of discussion in many scientific publications and in patient–physician encounters. In systemic lupus erythematosus (SLE), the concept of remission has also been discussed extensively. Remission in SLE is widely understood as a desirable disease state that should …

Referência(s)